טוען...
Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
BACKGROUND: Vesicular monoamine transporter 2 (VMAT2) inhibitors can improve hyperkinetic movements, and are effective treatment options for chorea of Huntington disease (HD). Tetrabenazine was assessed for treating chorea in the TETRA-HD trial, and while efficacious, there are tolerability concerns...
שמור ב:
| הוצא לאור ב: | J Clin Mov Disord |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5331691/ https://ncbi.nlm.nih.gov/pubmed/28265459 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40734-017-0051-5 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|